**Core Concept:** Anti-VEGF agents are a class of medications that target vascular endothelial growth factor (VEGF), a protein involved in promoting angiogenesis (new blood vessel formation) and vascular permeability. These agents are commonly used in the treatment of various ocular and systemic disorders characterized by abnormal blood vessel growth.

**Why the Correct Answer is Right:** Bevacizumab (Option D) is a monoclonal antibody that specifically binds to VEGF-A, neutralizing its effects and inhibiting angiogenesis. It is most widely known for its use in the treatment of certain types of cancer and is also used off-label for the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME).

**Why Each Wrong Option is Incorrect:**

A. Eylea (aflibercept) is a recombinant fusion protein that binds to multiple forms of VEGF-A and placental growth factor (PGF), inhibiting angiogenesis and reducing vascular permeability. This drug is commonly used for the treatment of AMD and DME.

B. Lucentis (ranibizumab) is a monoclonal antibody fragment that binds to VEGF-A, inhibiting its interaction with its receptors and preventing angiogenesis. This drug is also used for the treatment of AMD and DME.

C. Avastin is a monoclonal antibody that binds to VEGF-A, blocking its interaction with its receptors and inhibiting angiogenesis. It is used off-label for various cancer treatments and is not specifically approved for ocular indications.

**Clinical Pearl:** Anti-VEGF agents are a crucial component of modern medical therapy for various ocular and systemic diseases. However, their use requires careful consideration of potential side effects and complications, including endophthalmitis and thromboembolic events. Patients with these conditions should be closely monitored under the supervision of a qualified ophthalmologist or oncologist experienced in anti-VEGF therapy.